BNP Paribas Financial Markets
CTKB icon

BNP Paribas Financial Markets’s Cytek Biosciences CTKB Stock Holding History

BNP Paribas Financial Markets’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$952K Buy
215,010
+136,966
+175% +$585K ﹤0.01% 3350
2026
Q1 		$341K Sell
78,044
-28,238
-27% -$133K ﹤0.01% 3788
2025
Q4 		$537K Buy
106,282
+82,466
+346% +$383K ﹤0.01% 3534
2025
Q3 		$82.6K Buy
23,816
+11,838
+99% +$44.4K ﹤0.01% 4382
2025
Q2 		$40.7K Sell
11,978
-81,853
-87% -$273K ﹤0.01% 4336
2025
Q1 		$376K Sell
93,831
-114,833
-55% -$595K ﹤0.01% 3336
2024
Q4 		$1.35M Buy
+208,664
New +$1.24M ﹤0.01% 2626

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BNP Paribas Financial Markets's CTKB Position: Q2 2026 in Review

BNP Paribas Financial Markets increased its Cytek Biosciences (CTKB) stake by 175% in Q2 2026, buying an estimated $585K and bringing the position to 215,010 shares worth $952K. The position accounts for ﹤0.01% of the portfolio, ranked #3350.

BNP Paribas Financial Markets first reported a position in CTKB in Q4 2024 and has held it in 7 quarters since. The position peaked at $1.35M in Q4 2024. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • BNP Paribas Financial Markets held 215,010 shares of Cytek Biosciences worth $952K as of Q2 2026.
  • BNP Paribas Financial Markets bought 136,966 Cytek Biosciences shares in Q2 2026, an estimated $585K.
  • Cytek Biosciences made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3350 holding.
  • BNP Paribas Financial Markets first reported a position in Cytek Biosciences in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Cytek Biosciences position peaked at $1.35M in Q4 2024.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.